Form 4: Gyre Therapeutics President Sells Shares Under 10b5-1 Trading Plan

Songjiang Ma, President of Gyre Therapeutics, sold shares of common stock on March 17 and 18, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• Songjiang Ma, President of Gyre Therapeutics, sold 2,000 shares of common stock on March 17, 2025, at a weighted average price of $12.09 per share.
• The shares were sold in multiple transactions with prices ranging from $11.795 to $12.38.
• On March 18, 2025, Ma sold an additional 242 shares at a weighted average price of $10.24 per share, with individual prices ranging from $10.02 to $10.33.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on September 13, 2024.
• Following these transactions, Ma directly owns no shares, but indirectly owns 2,829,018 shares through a spouse.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing stock sales by an executive. The use of a 10b5-1 plan suggests the sales were pre-planned and doesn't necessarily indicate a negative outlook, but it also doesn't provide any particularly positive information.

Industry Context

Sales by company presidents are common and often pre-planned to avoid insider trading accusations. The use of a 10b5-1 plan suggests the sales were scheduled in advance.

Stakeholder Impact

• The stock sales could have a minor negative impact on shareholder sentiment, although the use of a 10b5-1 plan mitigates concerns about insider trading.

Key Dates

Keywords

Form 4, Gyre Therapeutics, Songjiang Ma, Stock Sale, 10b5-1 Trading Plan, Insider Trading